Stay on ICS: analysis shows no harm or benefit in COVID-19

Regular use of inhaled corticosteroids (ICS) does not appear to either increase or decrease mortality from COVID-19 in patients with asthma or COPD, say UK researchers. In response to speculation that ICS may confer a potential protective effect in COVID-19, analysis of a large database initially showed an increased risk of death related to ICS ...